Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Algernon Pharmaceuticals Inc. C.AGN

Alternate Symbol(s):  AGNPF

Algernon Pharmaceuticals Inc. is a clinical-stage drug development company. The Company is focused on developing repurposed therapeutic drugs in the areas of non-alcoholic steatohepatitis (NASH), a type of liver disease, chronic kidney disease (CKD), inflammatory bowel disease (IBD), idiopathic pulmonary fibrosis (IPF) and chronic cough as well as advancing a stroke program using N, N-Dimethyltryptamine (DMT). The Company operates through two segments, which includes the development of repurposed therapeutic drugs in Canada and the facilitation of the Company’s lead drug candidates into off-label phase II clinical trials (humans) in Australia. The Company's pipeline includes NP-251 (Repirinast) and AP-188 (DMT). The Company, through its subsidiary, Algernon NeuroScience Inc., is developing AP-188 (DMT) as a potential treatment for stroke and traumatic brain injury (TBI) recovery. Its NP-251 is being developed as a potential treatment for kidney inflammation and fibrosis.


CSE:AGN - Post by User

Post by CASHEAGLEon Jul 15, 2022 10:26am
134 Views
Post# 34826863

Libel and defamation behind a USERID

Libel and defamation behind a USERID
2022 February 9
Canada Easy Investment Store Corporation v. MacAskill2022 BCSC 202

The British Columbia Supreme Court awarded defamation damages aggregating $190,000 to the plaintiffs over false and inflammatory statements on various blogs and websites and in emails containing links to the blog posts. General damages were assessed at $150,000 split equally between the corporate plaintiff and the individual plaintiff, an officer and director of the company.  The defendant, who did not show up for the summary trial, had asserted that one of his blogs served “6,000 eyeballs per day” and the Court held there was “an overwhelming body of evidence … that the posts authored [by the defendant] were published on the internet and read by many people.”  Each plaintiff was also awarded $5,000 aggravated damages on the basis the defendant was motivated by actual mala fides and also displayed a reckless disregard for the truth.  Each plaintiff was also awarded $15,000 punitive damages in order to “deter [the defendant] from engaging in … manipulative, harmful and socially destructive behaviour in the future.”  Special costs were also ordered in favour of the plaintiffs, as well as a permanent injunction.  The Court also made an order that the plaintiffs had made out a prima facie case that the defendant had deliberately violated a pre-trial injunction and expressed the hope he would be deterred from further harassing conduct, rendering a final finding of contempt unnecessary.

 
<< Previous
Bullboard Posts
Next >>